Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.12888
Abstract: Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor developed to treat anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open‐label, 24‐week study investigated the efficacy and safety of roxadustat in Japanese… read more here.
Keywords: esa esa; chronic kidney; open label; patients anemia ... See more keywords